We are live on
!
Find out more
TA
Tamarack Advisers Portfolio holdings
AUM
$2.12M
1-Year Est. Return
58.09%
This Fund
S&P 500
This Quarter
Est. Return
+22.63%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$480M
AUM Growth
+$155M
(+48%)
Cap. Flow
+$85.5M
Cap. Flow
% of AUM
17.81%
Top 10 Holdings %
Top 10 Hldgs %
55.71%
Holding
53
New
19
Increased
14
Reduced
7
Closed
9
Top Buys
| 1 |
Medtronic
MDT
|
+$13.8M |
| 2 |
SNRHU
Senior Connect Acquisition Corp. I Unit
SNRHU
|
+$9.8M |
| 3 |
Opendoor
OPEN
|
+$9.75M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$9.64M |
| 5 |
NUAN
Nuance Communications, Inc.
NUAN
|
+$8.53M |
Top Sells
| 1 |
Bio-Rad Laboratories Class A
BIO
|
+$7.73M |
| 2 |
AdaptHealth
AHCO
|
+$6.65M |
| 3 |
Phreesia
PHR
|
+$5.36M |
| 4 |
MDRX
Veradigm Inc. Common Stock
MDRX
|
+$4.84M |
| 5 |
Plexus
PLXS
|
+$3.36M |
Sector Composition
| 1 | Healthcare | 82.05% |
| 2 | Technology | 6.99% |
| 3 | Consumer Staples | 3.31% |
| 4 | Real Estate | 1.49% |
| 5 | Consumer Discretionary | 1.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Pacira BioSciences
PCRX
$994M
| $43.6M | 9.08% |
735,000
+80,000
| +12% | +$4.68M |
|
|
2
Medtronic
MDT
$106B
| $43.3M | 9.02% |
375,000
+125,000
| +50% | +$13.8M |
|
3
United Therapeutics
UTHR
$22.7B
| $28.1M | 5.86% |
183,000
+23,000
| +14% | +$3.02M |
|
4
Rigel Pharmaceuticals
RIGL
$752M
| $26M | 5.41% |
745,000
-5,000
| -0.7% | -$145K |
|
|
NUAN
5
DELISTED
Nuance Communications, Inc.
NUAN
| $25M | 5.21% |
575,000
+225,000
| +64% | +$8.53M |
|
|
MDRX
6
DELISTED
Veradigm Inc. Common Stock
MDRX
| $21.6M | 4.5% |
1,500,000
-400,000
| -21% | -$4.84M |
|
7
Labcorp
LH
$23.1B
| $20.4M | 4.25% |
116,400
+23,280
| +25% | +$4.02M |
|
|
HOLX
8
DELISTED
Hologic
HOLX
| $20M | 4.16% |
275,000
-25,000
| -8% | -$1.76M |
|
9
Quest Diagnostics
DGX
$23.2B
| $19.8M | 4.13% |
165,000
+65,000
| +65% | +$7.92M |
|
10
AtriCure
ATRC
$1.77B
| $19.6M | 4.09% |
366,400
+16,400
| +5% | +$709K |
|
11
Perrigo
PRGO
$1.47B
| $16.6M | 3.47% |
375,000
-55,000
| -13% | -$2.55M |
|
12
Turning Point Brands
TPB
$1.6B
| $15.9M | 3.31% |
370,000
+165,000
| +80% | +$6.23M |
|
13
ICU Medical
ICUI
$3.95B
| $15.5M | 3.22% |
73,000
+12,000
| +20% | +$2.33M |
|
14
Lantheus
LNTH
$6.9B
| $13M | 2.72% |
950,000
| – | – |
|
15
RadNet
RDNT
$4.81B
| $12.1M | 2.52% |
650,000
+25,000
| +4% | +$442K |
|
16
SI-BONE Inc
SIBN
$762M
| $11.3M | 2.34% |
385,000
+140,000
| +57% | +$3.41M |
|
|
SNRHU
17
DELISTED
Senior Connect Acquisition Corp. I Unit
SNRHU
| $9.84M | 2.05% |
+950,000
| New | +$9.8M |
|
|
18
Vertex Pharmaceuticals
VRTX
$123B
| $9.59M | 2% |
+42,000
| New | +$9.64M |
|
|
19
Phreesia
PHR
$659M
| $9.22M | 1.92% |
175,000
-125,000
| -42% | -$5.36M |
|
|
OPTN
20
DELISTED
OptiNose
OPTN
| $8.41M | 1.75% |
131,467
+8,134
| +7% | +$498K |
|
21
Viatris
VTRS
$20.1B
| $8.38M | 1.75% |
450,000
+400,000
| +800% | +$6.52M |
|
|
22
Plexus
PLXS
$6.66B
| $7.88M | 1.64% |
100,000
-45,000
| -31% | -$3.36M |
|
|
23
Opendoor
OPEN
$4.25B
| $7.16M | 1.49% |
+465,000
| New | +$9.75M |
|
|
STRM
24
DELISTED
Streamline Health Solutions
STRM
| $6.93M | 1.44% |
287,059
| – | – |
|
|
LMNX
25
DELISTED
Luminex Corp
LMNX
| $6.04M | 1.26% |
+250,000
| New | +$5.81M |
|
Similar funds
SCM
LBC
ICM
LCMP
GIP
STC
GC
DU
Tamarack Advisers's Q4 2020 Portfolio in Review
As of Q4 2020, Tamarack Advisers held 53 positions worth $480M, up 48% from $324M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Tamarack Advisers deployed $85.5M of net new capital in Q4 2020, opening 19 new positions and adding to 14 existing holdings. Its largest new stake was Senior Connect Acquisition Corp. I Unit: 950,000 shares worth $9.84M.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 90% a quarter earlier, followed by Technology and Consumer Staples.
On the sell side, the largest reduction was Phreesia, an estimated $5.36M trimmed.
- Tamarack Advisers's largest Q4 2020 buy was Senior Connect Acquisition Corp. I Unit: 950,000 shares worth $9.84M.
- Tamarack Advisers added most to Medtronic in Q4 2020, an estimated $13.8M increase.
- Tamarack Advisers's biggest Q4 2020 reduction was Phreesia, cutting an estimated $5.36M.
- Tamarack Advisers fully exited Bio-Rad Laboratories Class A in Q4 2020, selling an estimated $7.73M.
- Tamarack Advisers's ten largest holdings make up 56% of its $480M portfolio in Q4 2020.
- Tamarack Advisers opened 19 new positions and closed 9 in Q4 2020.
- Tamarack Advisers's portfolio value rose 48% quarter-over-quarter to $480M.
Based on Tamarack Advisers's 13F filing for Q4 2020, filed 10 Feb 2021.